Tadaaki Yamada

50PUBLICATIONS
78CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMolecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Sep 11, 2026
Osimertinib vs. erlotinib combined with an angiogenesis inhibitor in EGFR-mutated non-small cell lung cancer with malignant pleural effusion: a retrospective cohort study.

|Aug 05, 2026
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC.

|Apr 12, 2026
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.

Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada

|Jan 20, 2026
Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.

Kenji Morimoto, Tadaaki Yamada, Naoya Nishioka

|Dec 10, 2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.

Yusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada

|Jul 21, 2025
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.

Kenji Morimoto, Tadaaki Yamada, Naoki Furuya

Pageof 9

Frequent Collaborators

15 joint publications

Takayuki Takeda

15 joint publications

Koichi Takayama

13 joint publications

Akihiro Yoshimura

9 joint publications

Junji Uchino